Brad Pitt and his girlfriend Nicole Poturalski split up. Here's what you want to know about it.
Brad Pitt and his girlfriend Nicole Poturalski split up. Here's what you want to know about it.
The "Global Geothermal Power Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
When Edinson Cavani joined Manchester United on transfer deadline day in October it was widely described as a "panic signing" with the 33-year-old's arrival viewed as a desperate deal by a club who had failed to get their main targets. His goals were superbly taken, his movement in the box won plaudits from his manager Ole Gunnar Solskjaer and many observers and, even though it had only been 45 minutes, he looked far from a player past his sell-by date. "For me, he's one of those strikers that can smell the goal, as you saw twice," said United midfielder Bruno Fernandes.
New Jersey Resources (NYSE: NJR) (the "company" or "NJR") today will host a virtual 2020 Analyst Day to provide an update on the Company’s strategic plan and financial growth targets, including:
The "Biochar Market, Size, Share, Outlook and COVID-19 Strategies, Global Forecasts from 2019 to 2026" report has been added to ResearchAndMarkets.com's offering.
The Transaction Monitoring Solutions Market will grow by USD 9.97 bn during 2020-2024
To empower its customers in the fight against financial crime, Computer Services, Inc. (CSI) (OTCQX: CSVI), a provider of end-to-end fintech and regtech solutions, has partnered with Featurespace™, a leading provider of Enterprise Financial Crime prevention software, to launch a holistic anti-money laundering (AML) solution: WatchDOG® AML.
Apnimed to Participate in Fireside Chat at the Evercore ISI HealthCONx Conference
Today, New Jersey Resources (NYSE: NJR) reported results for the fourth quarter and fiscal 2020. Highlights included:
Save on tire and snow tire deals at the Cyber Monday sale, featuring the best BFGoodrich, Discount Tire, Tire Rack and Firestone discounts
The "Luxury Vinyl Tile (LVT) Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarkets.com's offering.
Doctors are studying the impact of COVID-19 on pregnant women and their unborn babies in Singapore, where an infant delivered by an infected mother earlier this month had antibodies against the virus but did not carry the disease. The ongoing study among the city-state's public hospitals adds to international efforts to better understand whether the infection or antibodies can be transferred during pregnancy, and if the latter offers an effective shield against the virus. The World Health Organisation says while some pregnant women have an increased risk of developing severe COVID-19, it is not yet known whether an infected pregnant woman can pass the virus to her foetus or baby during pregnancy or delivery.
Dublin, Nov. 30, 2020 (GLOBE NEWSWIRE) -- The "Asia Pacific Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering. Asia Pacific antibiotics market will grow by 4.1% annually with a total addressable market cap of $253.1 billion over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.This report is based on a comprehensive research of the entire Asia Pacific antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.In-depth qualitative analyses include identification and investigation of the following aspects: Market StructureGrowth DriversRestraints and ChallengesEmerging Product Trends & Market OpportunitiesPorter's Five Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.Specifically, potential risks associated with investing in Asia Pacific antibiotics market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.Key Topics Covered: 1 Introduction1.1 Industry Definition and Research Scope1.1.1 Industry Definition1.1.2 Research Scope1.2 Research Methodology1.2.1 Overview of Market Research Methodology1.2.2 Market Assumption1.2.3 Secondary Data1.2.4 Primary Data1.2.5 Data Filtration and Model Design1.2.6 Market Size/Share Estimation1.2.7 Research Limitations1.3 Executive Summary2 Market Overview and Dynamics2.1 Market Size and Forecast2.1.1 Impact of COVID-19 on the Market2.2 Major Growth Drivers2.3 Market Restraints and Challenges2.4 Emerging Opportunities and Market Trends2.5 Porter's five Forces Analysis3 Segmentation of Asia Pacific Market by Drug Class3.1 Market Overview by Drug Class3.2 Cephalosporin3.3 Penicillin3.4 Macrolides3.5 Fluoroquinolones3.6 Quinolones3.7 Monobactam3.8 Aminoglycosides3.9 Carbapenem3.10 Other Drug Classes4 Segmentation of Asia Pacific Market by Action Mechanism4.1 Market Overview by Action Mechanism4.2 Cell Wall Synthesis Inhibitors4.3 Mycolic Acid Inhibitors4.4 RNA Synthesis Inhibitors4.5 DNA Synthesis Inhibitors4.6 Protein Synthesis Inhibitors4.7 Other Mechanisms5 Segmentation of Asia Pacific Market by Drug Origin5.1 Market Overview by Drug Origin5.2 Natural Antibiotics5.3 Semi-synthetic Antibiotics5.4 Synthetic Antibiotics6 Segmentation of Asia Pacific Market by Activity Spectrum6.1 Market Overview by Activity Spectrum6.2 Broad-spectrum Antibiotics6.3 Narrow-spectrum Antibiotics7 Segmentation of Asia Pacific Market by Route of Administration7.1 Market Overview by Route of Administration7.2 Oral Administration7.3 Intravenous Administration7.4 Other Administration Routes8 Segmentation of Asia Pacific Market by Drug Type8.1 Market Overview by Drug Type8.2 Brand Antibiotics8.3 Generic Antibiotics9 Asia-Pacific Market 2019-2030 by Country9.1 Overview of Asia-Pacific Market9.2 Japan9.3 China9.4 Australia9.5 India9.6 South Korea9.7 Rest of APAC Region10 Competitive Landscape10.1 Overview of Key Vendors10.2 New Product Launch, Partnership, Investment, and M&A10.3 Company Profiles Abbott LaboratoriesAstellas PharmaAstraZeneca PlcBayer AGBristol Myers Squibb CompanyCipla Inc.Dr. Reddy's Laboratories Ltd.Eli Lilly and CompanyF. Hoffmann-La Roche Ltd.Gilead Sciences, Inc.GlaxoSmithKline plc.Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)Mayne Pharma Group Ltd.MELINTA THERAPEUTICS, INC.Merck KGaANovartis AGPfizer Inc.SanofiSun Pharmaceutical Industries Ltd. 11 Investing in Asia Pacific Market: Risk Assessment and Management11.1 Risk Evaluation of Asia Pacific Market11.2 Critical Success Factors (CSFs) For more information about this report visit https://www.researchandmarkets.com/r/2ply87 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
ZoomInfo Technologies Inc. ("ZoomInfo") today announced that certain selling stockholders of ZoomInfo, including investment funds affiliated with TA Associates ("TA"), The Carlyle Group ("Carlyle") and 22C Capital LLC (together with TA and Carlyle, the "Selling Stockholders") have commenced an underwritten public offering of 12,500,000 shares of ZoomInfo’s Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of ZoomInfo’s Class A common stock.
UK now has access to seven million shots of two-dose vaccine — enough to inoculate 3.5 million Britons
The announcement comes just three weeks after the end of Wales’s 17-day firebreak lockdown.
Sweden's Telia Company will replace all 4G telecoms equipment from Huawei in Lithuania and will not use it for 5G networks, due to the geopolitical situation, its local head told the local BNS news agency. The United States has been leading a global push to exclude Chinese telecommunication companies such as Huawei and ZTE from communications networks for alleged security vulnerabilities, part or rising tensions between the two powers which saw both countries imposing economic sanctions and restricting rival diplomatic activities.
Summary “BRIC Cardiovascular Surgery Procedures Outlook to 2025” is a comprehensive databook report, covering key procedures data on the BRIC Cardiovascular Surgery Procedures.New York, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "BRIC Cardiovascular Surgery Procedures Outlook to 2025 - Coronary Artery Bypass Graft (CABG) Procedures and Isolated Valve Procedures" - https://www.reportlinker.com/p05993099/?utm_source=GNW The databook report provides procedure volumes within segments - Coronary Artery Bypass Graft (CABG) Procedures and Isolated Valve Procedures. The BRIC Cardiovascular Surgery Procedures report provides key information and data on - - Procedure volume data for Cardiovascular Surgery Procedures related to the country. Data is provided from 2015 to 2025. Scope BRIC Cardiovascular Surgery Procedures is segmented as follows - - Coronary Artery Bypass Graft (CABG) Procedures - Isolated Valve Procedures Reasons to Buy The BRIC Cardiovascular Surgery Procedures report helps you to develop - - Business strategies by identifying the key segments poised for strong growth in the future. - Market-entry and market expansion strategies. - Develop investment strategies by identifying the key segments expected to register strong growth in the near future.Read the full report: https://www.reportlinker.com/p05993099/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Solidium’s Annual General Meeting was held in Helsinki on 30 November 2020. The Annual General Meeting adopted the company’s financial statements for the financial year 1 July 2019–30 June 2020 and discharged the members of the Board of Directors and the CEO from liability. The Annual General Meeting decided not to distribute profits to the owner. For a term ending at the end of the next Annual General Meeting, the following persons were re-elected to the Board of Directors: Harri Sailas (Chairman), Aaro Cantell (Vice-Chairman), and Timo Ahopelto, Jannica Fagerholm, Marjo Miettinen, Laura Raitio and Kimmo Viertola as Board members. The Annual General Meeting confirmed the existing remuneration of the Board of Directors: Chairman of the Board of Directors shall receive a remuneration of EUR 5,500 per month, the Vice Chairman EUR 3,000 per month, and each member EUR 2,500 per month. In addition, a meeting remuneration of EUR 600 was confirmed for each meeting. KPMG Oy Ab, authorised public accountants, with APA Marcus Tötterman as the principal auditor, was re-appointed as Solidium’s auditor to serve for a term ending at the end of the next Annual General Meeting. Solidium Oy Further information: Harri Sailas, Chairman of the Board, call-back requests, Inka Virtanen, tel. +358 (0)10 830 8901 Solidium is a limited company wholly owned by the State of Finland. Its mission is to strengthen and stabilise Finnish ownership in nationally important companies and increase the value of its holdings in the long term. The basis and core objective of Solidium's strategy is proper, value-enhancing asset management of its current holdings. Through its stakes, Solidium is a minority owner in twelve listed companies: Elisa, Kemira, Konecranes, Metso Outotec, Nokia, Nokian Tyres, Outokumpu, Sampo, SSAB, Stora Enso, TietoEVRY and Valmet. The market value of Solidium’s investments is approximately EUR 7.7 billion. Further information: www.solidium.fi
LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST. A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Investors section under Events & Presentations. A replay will be available soon after the live presentation. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia. For further information, please visit www.gwpharm.com. Enquiries: GW Pharmaceuticals plc Scott Giacobello, Chief Financial Officer 760 795 2200
DGAP-News: Henri Broen Holding B.V. / Key word(s): Issue of Debt 30.11.2020 / 13:31 The issuer is solely responsible for the content of this announcement. The Dutch finance and management holding company Henri Broen Holding B.V. is extending the subscription phase of its 7.5% bond 2020/25. Professional investors and eligible counterparties pursuant to Section 67 of the German Securities Trading Act may now subscribe to the bond until 16 December in a private placement. The start of trading in the over-the-counter market of the Frankfurt Stock Exchange is 18 December. "We are meeting with a lot of positive feedback, but decision-making processes still take a long time - this is certainly also due to the current market situation. We want to give investors the necessary time and have therefore decided once again to extend the subscription period," says Carsten Mainitz, CFO of the company. Interested professional investors and suitable counterparties can find comprehensive information about the bond issue and the Koningsbosch project at www.hbroen.nl. Contact for investors and press: Carsten Mainitz CFO email@example.com M: +49(0)179 145 39 75 Henri Broen Holding B.V. Nimweger Street 21 47533 Kleve www.hbroen.nl 30.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de